Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

Impact of therapy escalation on ambulatory care costs among patients with type 2 diabetes in France.

Guelfucci F, Clay E, Aballéa S, Lassalle R, Moore N, Toumi M.

BMC Endocr Disord. 2013 Apr 29;13:15. doi: 10.1186/1472-6823-13-15.

2.

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.

PMID:
15099124
4.
5.

Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: an analysis of third-party managed care claims data.

Lee WC, Balu S, Cobden D, Joshi AV, Pashos CL.

Clin Ther. 2006 Oct;28(10):1712-25; discussion 1710-1. Erratum in: Clin Ther. 2006 Nov;28(11):1968-9.

PMID:
17157128
6.

Cost of self-monitoring of blood glucose in the United States among patients on an insulin regimen for diabetes.

Yeaw J, Lee WC, Aagren M, Christensen T.

J Manag Care Pharm. 2012 Jan-Feb;18(1):21-32.

7.
8.

Diabetes prevalence and hospital and pharmacy use in the Veterans Health Administration (1994). Use of an ambulatory care pharmacy-derived database.

Pogach LM, Hawley G, Weinstock R, Sawin C, Schiebe H, Cutler F, Zieve F, Bates M, Repke D.

Diabetes Care. 1998 Mar;21(3):368-73.

PMID:
9540017
9.
10.

Resource utilization and costs associated with using insulin therapy within a newly diagnosed type 2 diabetes mellitus population.

Bell K, Parasuraman S, Raju A, Shah M, Graham J, Denno M.

J Manag Care Spec Pharm. 2015 Mar;21(3):220-8a.

11.

Total and component health care costs in a non-Medicare HMO population of patients with and without type 2 diabetes and with and without macrovascular disease.

Gandra SR, Lawrence LW, Parasuraman BM, Darin RM, Sherman JJ, Wall JL.

J Manag Care Pharm. 2006 Sep;12(7):546-54.

12.

Cost of diabetes: comparison of disease-attributable and matched cohort cost estimation methods.

Tunceli O, Wade R, Gu T, Bouchard JR, Aagren M, Luo W.

Curr Med Res Opin. 2010 Aug;26(8):1827-34. doi: 10.1185/03007995.2010.488544.

PMID:
20491613
13.
14.

[Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].

Llorca PM, Miadi-Fargier H, Lançon C, Jasso Mosqueda G, Casadebaig F, Philippe A, Guillon P, Mehnert A, Omnès LF, Chicoye A, Durand-Zaleski I.

Encephale. 2005 Mar-Apr;31(2):235-46. Review. French.

PMID:
15959450
15.

A comparison of costs among patients with type 2 diabetes mellitus who initiated therapy with exenatide or insulin glargine.

Misurski D, Lage MJ, Fabunmi R, Boye KS.

Appl Health Econ Health Policy. 2009;7(4):245-54. doi: 10.2165/11318730-000000000-00000.

PMID:
19905038
16.
17.

[Costs of type 2 diabetes in Germany. Results of the CODE-2 study].

Liebl A, Neiss A, Spannheimer A, Reitberger U, Wagner T, Görtz A.

Dtsch Med Wochenschr. 2001 May 18;126(20):585-9. German.

PMID:
11402924
18.

Antidiabetic therapy in real practice: indicators for adherence and treatment cost.

Colombo GL, Rossi E, De Rosa M, Benedetto D, Gaddi AV.

Patient Prefer Adherence. 2012;6:653-61. doi: 10.2147/PPA.S33968. Epub 2012 Sep 14.

19.

Self blood glucose monitoring in type 2 diabetes. A financial impact analysis based on UK primary care.

Belsey JD, Pittard JB, Rao S, Urdahl H, Jameson K, Dixon T.

Int J Clin Pract. 2009 Mar;63(3):439-48. doi: 10.1111/j.1742-1241.2008.01992.x.

PMID:
19222629
20.

Health care utilization and costs in type 2 diabetes mellitus and their association with renal impairment.

Burke J, Kovacs B, Borton L, Sander S.

Postgrad Med. 2012 Mar;124(2):77-91. doi: 10.3810/pgm.2012.03.2539.

PMID:
22437218

Supplemental Content

Support Center